Copyright © 2003 by the European Society of Cardiology.
Clinical research
Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention1
a Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, and School of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China
* Corresponding author. Yu-An Ding, Division of Cardiology, Taipei Veterans General Hospital, 201, Sec. 2, Shih-Pai Road, Taipei, Taiwan, Republic of China. Tel.: +886-2-2875-7229; fax: +886-2-2875-3580
E-mail address: yading{at}vghtpe.gov.tw
Received 30 March 2003; revised 30 July 2003; accepted 21 August 2003
Abstract
Aims We investigated the predictive value of plasma concentration of asymmetrical dimethylarginine (ADMA) on clinical outcome in patients undergoing percutaneous coronary intervention (PCI).
Methods and results One-hundred and fifty-three consecutive patients with stable angina and undergoing PCI were prospectively enrolled for clinical follow-up. Plasma ADMA levels were determined before procedure by high performance liquid chromatography. The major adverse cardiovascular events included cardiovascular death, myocardial infarction, and repeat revascularization of target vessels. Patients were grouped into tertiles according to their plasma ADMA levels. Over a follow-up period of 16 months (median), cardiovascular events occurred in 6 patients of tertile I (<0.50µM), in 17 patients of tertile II (0.50–0.62µM), and in 28 patients of tertile III (>0.62µM), P<0.001. By multivariate analysis, tertiles of ADMA levels were independently associated with a higher risk of adverse cardiovascular events after PCI (relative risk: tertile II vs I: 3.0 [1.2–7.7], P=0.022; tertile III vs I: 5.3 [2.2–12.9], P<0.001). Moreover, plasma ADMA level in the highest tertile also appeared as a significant risk factor of subsequent death and non-fatal myocardial infarction after PCI (tertile III vs I, P=0.04).
Conclusion Pre-procedural plasma ADMA levels may independently predict subsequent adverse cardiovascular events in patients undergoing PCI. Measurement of plasma ADMA levels could provide a rationale for risk stratification of patients by measuring ADMA levels before intervention.
Key Words: Asymmetrical dimethylarginine • Nitric oxide • Percutaneous coronaryintervention
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- When the endothelium cannot say ‘NO’ anymore: ADMA, an endogenous inhibitor of NO synthase, promotes cardiovascular disease
- Rainer H Böger
EHJ 2003 24: 1901-1902.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  C. Antoniades, C. Shirodaria, P. Leeson, A. Antonopoulos, N. Warrick, T. Van-Assche, C. Cunnington, D. Tousoulis, R. Pillai, C. Ratnatunga, et al. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis Eur. Heart J., May 1, 2009; 30(9): 1142 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Boger, L. M. Sullivan, E. Schwedhelm, T. J. Wang, R. Maas, E. J. Benjamin, F. Schulze, V. Xanthakis, R. A. Benndorf, and R. S. Vasan Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community Circulation, March 31, 2009; 119(12): 1592 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Wu, S.-C. Wen, C.-W. Yang, S.-Y. Pu, K.-C. Tsai, and J.-W. Chen Plasma ADMA Predicts Restenosis of Arteriovenous Fistula J. Am. Soc. Nephrol., January 1, 2009; 20(1): 213 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zeller, C. Korandji, J.-C. Guilland, P. Sicard, C. Vergely, L. Lorgis, J.-C. Beer, L. Duvillard, A.-C. Lagrost, D. Moreau, et al. Impact of Asymmetric Dimethylarginine on Mortality After Acute Myocardial Infarction Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 954 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Leong, D. Zylberstein, I. Graham, L. Lissner, D. Ward, J. Fogarty, C. Bengtsson, C. Bjorkelund, D. Thelle, and for The Swedish-Irish-Norwegian (SIN) Collaboratio Asymmetric Dimethylarginine Independently Predicts Fatal and Nonfatal Myocardial Infarction and Stroke in Women: 24-Year Follow-Up of the Population Study of Women in Gothenburg Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 961 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lajer, L. Tarnow, A. Jorsal, T. Teerlink, H.-H. Parving, and P. Rossing Plasma Concentration of Asymmetric Dimethylarginine (ADMA) Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic Nephropathy Diabetes Care, April 1, 2008; 31(4): 747 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Gozal, L. Kheirandish-Gozal, L. D. Serpero, O. Sans Capdevila, and E. Dayyat Obstructive Sleep Apnea and Endothelial Function in School-Aged Nonobese Children: Effect of Adenotonsillectomy Circulation, November 13, 2007; 116(20): 2307 - 2314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ledoux, M. Monchi, J.-P. Chapelle, and P. Damas Cystatin C blood level as a risk factor for death after heart surgery Eur. Heart J., August 1, 2007; 28(15): 1848 - 1853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. I. Boger, T. K. Rudolph, R. Maas, E. Schwedhelm, E. Dumbadze, A. Bierend, R. A. Benndorf, and R. H. Boger Asymmetric Dimethylarginine Determines the Improvement of Endothelium-Dependent Vasodilation by Simvastatin: Effect of Combination With Oral L-Arginine J. Am. Coll. Cardiol., June 12, 2007; 49(23): 2274 - 2282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Maas, F. Schulze, J. Baumert, H. Lowel, K. Hamraz, E. Schwedhelm, W. Koenig, and R. H. Boger Asymmetric Dimethylarginine, Smoking, and Risk of Coronary Heart Disease in Apparently Healthy Men: Prospective Analysis from the Population-Based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg Study and Experimental Data Clin. Chem., April 1, 2007; 53(4): 693 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Konishi, K. Sydow, and J. P. Cooke Dimethylarginine Dimethylaminohydrolase Promotes Endothelial Repair After Vascular Injury J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1099 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Meinitzer, U. Seelhorst, B. Wellnitz, G. Halwachs-Baumann, B. O. Boehm, B. R. Winkelmann, and W. Marz Asymmetrical Dimethylarginine Independently Predicts Total and Cardiovascular Mortality in Individuals with Angiographic Coronary Artery Disease (The Ludwigshafen Risk and Cardiovascular Health Study) Clin. Chem., February 1, 2007; 53(2): 273 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Yang and X.-F. Ming Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin. Med. Res., March 1, 2006; 4(1): 53 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Krempl, R. Maas, K. Sydow, T. Meinertz, R. H. Boger, and J. Kahler Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events Eur. Heart J., September 2, 2005; 26(18): 1846 - 1851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schnabel, S. Blankenberg, E. Lubos, K. J. Lackner, H. J. Rupprecht, C. Espinola-Klein, N. Jachmann, F. Post, D. Peetz, C. Bickel, et al. Asymmetric Dimethylarginine and the Risk of Cardiovascular Events and Death in Patients With Coronary Artery Disease: Results from the AtheroGene Study Circ. Res., September 2, 2005; 97(5): e53 - e59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H Boger Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials Vascular Medicine, July 1, 2005; 10(1_suppl): S19 - S25. [Abstract] [PDF]
|
|
|
|
|
|
V.-P. Valkonen, T.-P. Tuomainen, and R. Laaksonen DDAH gene and cardiovascular risk Vascular Medicine, July 1, 2005; 10(1_suppl): S45 - S48. [Abstract] [PDF]
|
|
|
|
|
|
R. Maas Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA) Vascular Medicine, July 1, 2005; 10(1_suppl): S49 - S57. [Abstract] [PDF]
|
|
|
|
|
|
R. H Boger Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials Vascular Medicine, May 1, 2005; 10(2_suppl): S19 - S25. [Abstract] [PDF]
|
|
|
|
|
|
V.-P. Valkonen, T.-P. Tuomainen, and R. Laaksonen DDAH gene and cardiovascular risk Vascular Medicine, May 1, 2005; 10(2_suppl): S45 - S48. [Abstract] [PDF]
|
|
|
|
|
|
R. Maas Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA) Vascular Medicine, May 1, 2005; 10(2_suppl): S49 - S57. [Abstract] [PDF]
|
|
|
|
 |
|
 R. H. Boger Asymmetric Dimethylarginine, an Endogenous Inhibitor of Nitric Oxide Synthase, Explains the "L-Arginine Paradox" and Acts as a Novel Cardiovascular Risk Factor J. Nutr., October 1, 2004; 134(10): 2842S - 2847S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H Boger When the endothelium cannot say 'NO' anymore: ADMA, an endogenous inhibitor of NO synthase, promotes cardiovascular disease Eur. Heart J., November 1, 2003; 24(21): 1901 - 1902. [Full Text] [PDF]
|
|
|
|
|
|
R. H Boger Asymmetric dimethylarginine (ADMA) modulates endothelial function - therapeutic implications Vascular Medicine, August 1, 2003; 8(3): 149 - 151. [PDF]
|
|